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Los Angeles, California; Boston, Massachusetts; and Gaithersburg, MarylandObjectives This study was designed for conducting a comparative evaluation of the healing response
after Watchman (WM) (Boston Scientiﬁc, Plymouth, Minnesota) and Amplatzer Cardiac Plug (ACP)
(St. Jude Medical, Minneapolis, Minnesota) in a canine left atrial appendage (LAA) model.
Background There is no direct comparison of the WM and ACP device in pre-clinical or clinical settings.
Methods The LAA from canine (n ¼ 6) and human (n ¼ 19) hearts were compared to determine the
feasibility of the canine model and its relevance to clinical applications. Subsequently, implantation of
WM and ACP in the canine LAA was performed (n ¼ 3 per device) to evaluate the device conformation
to the LA anatomy as well as the healing response at 28 days.
Results The LAA is a variable tubular structure in both canine and human hearts. Gross examination
showed that the WM was properly seated inside the LAA ostium, in comparison to the ACP where
the disk was outside of the LAA oriﬁce and extended to the edge of the left superior pulmonary
vein and mitral valve. At 28 days, complete neo-endocardial coverage of the WM was observed;
however, the ACP showed an incomplete covering on the disk surface especially at the lower edge
and end-screw hub regions.
Conclusions There are differences in conformation of LAA surrounding structures with variable
healing response between WM and ACP after LAA closure in the canine model. WM does not obstruct
or impact the LAA adjacent structures, resulting in a favorable surface recovery. In comparison, the
disk of ACP could potentially jeopardize LAA neighboring structures and leads to delayed healing.
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802Percutaneous approaches to occlude the left atrial appendage
(LAA) represent an emerging, device-based alternative to
long-term pharmacologic therapy in the prevention of
atrial ﬁbrillation (AF)-associated stroke. Several trans-
catheter devices have been developed (1,2). Currently, the
2 most commonly implanted devices, are the Watchman
(WM) (Boston Scientiﬁc, Plymouth, Minnesota), and the
Amplatzer Cardiac Plug (ACP) (St. Jude Medical, Min-
neapolis, Minnesota).
Anatomically, the LAA has a complex geometric
structure with an oval-shaped oriﬁce. It is a gestational
remnant that originates from primordial atrial tissue,
whereas the rest of the left atrium, which is smooth, is
formed from the absorption of the pulmonary veins and its
branches (3). The atrial appendage overlaps the pulmonary
trunk, bulging anteriorly, with its tip pointing cranially in
most cases (4). It is in close proximity with several adjacentAbbreviations
and Acronyms
ACP = Amplatzer Cardiac
Plug
AF = atrial ﬁbrillation
LA = left atrium
LAA = left atrial appendage
LCX = left circumﬂex artery
LSPV = left superior
pulmonary vein
MV = mitral valve
TEE = transesophageal
echocardiography
TIMI = Thrombolysis In
Myocardial Infarction
WM = Watchman left atrial
appendage systemstructures, including the lateral
ridge between the LAA ostium
and the left superior pulmonary
vein (LSPV), mitral valve (MV)
annulus, left main, left anterior
descending and the left cir-
cumﬂex (LCX) coronary ar-
teries, and the great cardiac vein.
The LAA is a trabeculated
structure that is described to be
3 larger in volume in patients
with AF than in those without
AF. It is believed to be the
source of thrombosis in AF that
may lead to systemic emboli and
stroke (4,5). Therefore, we
compared the LAA of human
and canine anatomies to under-
stand the relevance of the ﬁnd-ings of WM and ACP when implanted in the LAA canine
model.
Whereas both devices have shown reasonable safety and
efﬁcacy in clinical and pre-clinical settings (6–10), there has
been no prospective study comparing the 2 devices. The
current pre-clinical study was therefore designed to evaluate
the healing response of the 2 devices in a 28-day canine
model. In addition, we validated in vitro the canine model
for pre-clinical testing.
Methods
Measurement of LAA and surrounding structures in canines
and humans. Six healthy canine (25.2  4.5 kg, 7 to
25 months of age in either sex) hearts and 19 human
(101.4  19.8 kg, 18 to 78 years of age in either sex) hearts
from the CVPath autopsy registry were selected to compare
the LAA dimension and the relationship of the LAA withthe adjacent structures. Each heart was incised through the
roof of the LA and opened along the posterior ventricular
septum to expose the LAA and surrounding anatomic
structures. Photographs of the external surface of the LAA
and the opened LA were obtained. LAA is lined by
pectinate muscle, whereas the LA is a smooth structure
and the measurements are taken at this transition zone in
the long- and short-axes of the LAA ostium (11). Mea-
surements included: 1) external length of the LAA; 2)
distance from the LAA ostium to the left main coronary
artery bifurcation; 3) the closest distance from LAA
ostium to the LCX; 4) LAA oriﬁce dimension, in the long
and short axes; 5) distance from LAA ostium to the LSPV;
and 6) distance from LAA ostium to the MV annulus.
Device characteristics. The WM LAA system consists of
a parachute-shaped device with a self-expanding nitinol
frame structure covered on the proximal half with a 160-mm
permeable polyester fabric membrane (12). It has a row of
ﬁxation barbs at mid-perimeter to help secure the device in
the LAA. Following successful deployment, the device
acts as a ﬁlter in the initial phase allowing passage of blood
but not thrombi. Subsequently over the next few months,
the surface of the device is covered with neo-endocardial
tissue that is impermeable to both blood and thrombi. The
surface membrane can lead to a thrombus formation, thus
the need for continuation of antithrombotic agents until
the device is completely endothelialized. The device is
available in 5 sizes ranging from 21 to 33 mm and is
deployed using a 12-F delivery system. To ensure adequate
closure and stability, the device that is chosen is 10% to 20%
larger than the LAA ostium.
The ACP LAA system is a self-expanding device con-
structed from nitinol and consists of a lobe and a disk
connected by a central waist. The lobe has ﬁxation wires to
ensure its stabilization, and the disk of the ACP device is
placed in the outer part of the LAA ostium. The device is
available in 8 different sizes based on the lobe diameter,
that is, 16 to 30 mm, in stepwise 2-mm increments. The
appropriate device chosen is usually 3 to 4 mm larger than
the diameter of the proximal part of the LAA body
(landing zone). The diameter of the proximal disk is
greater than the distal lobe diameter by 4 to 6 mm and is
connected by a disk end-screw hub with the device
intended to cover the mouth of the ostium.
Ex vivo device implantation. Unﬁxed hearts from male
mongrel canine (21 kg, 8 months of age) were obtained, and
the right atrium and atrial septal wall were carefully trimmed
to allow deployment of either theWMor ACP into the LAA
under direct visualization. The smallest devices fromWM(21
mm) and ACP (16-mm lobe with 20-mm disk) were selected
and alternately placed in the canine hearts. Photographs of
the device surfaces after each deployment were obtained. The
device conformation to the LAA, and the relationship to
the LSPV as well as the annulus of the MV were assessed.
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803In vivo device implantation. All protocols were approved by
the Animal Care and Use Committee and complied with all
animal use regulations as set forth in the Animal Welfare
Act, 9, Code of Federal Regulations, and the American
Association for the Accreditation of Laboratory Animal
Care as outlined in the National Research Council’s Guide
for the Care and Use of Laboratory Animals. All devices
were deployed by an operator experienced in the use of both
the devices.
WM (n ¼ 3) and ACP (n ¼ 3) were implanted in 6
mongrel adult dogs (26.6  1.3 kg, 8 to 15 months of age).
Animals received a combination of warfarin 6 mg/day and
aspirin 81 mg/day 1 day prior to the procedure and daily
thereafter until termination. The international normalized
ratio (INR) was monitored throughout the study and
medications were adjusted to maintain the international
normalized ratio between 2.0 and 3.0. The electrocardio-
gram, invasive blood pressure, end tidal CO2, functional O2
saturation, and body temperature were continuously moni-
tored during the device implantation.
Procedure. The devices were deployed under both trans-
esophageal echocardiographic (TEE) and ﬂuoroscopic
guidance. Catheterization through both the femoral vein and
arterial access was followed by heparinization (200 U/kg) to
maintain an active clotting time of 250 to 300 s. Before
device deployment, TEE was obtained to determine the
LAA size (mm). Following transseptal puncture, the LAA
was engaged using a pigtail catheter with the delivery sheath,
and contrast was injected to deﬁne the LAA anatomy. LAA
size was measured again via the right anterior oblique
view. Both appropriately sized (per the manufacturers’ in-
structions for use) WM and ACP devices were selected
and implanted in the LAA, in alternating animals. Proper
device positioning and stability was conﬁrmed by TEE and
ﬂuoroscopy prior to releasing each device. Immediately post-
deployment, TEE and coronary angiography were per-
formed to evaluate device position, any leakage around the
device, pericardial effusion, MV function, and LCX ﬂow.
These measurements were repeated on day 28 just prior
to euthanasia.
Histopathology evaluation. The hearts were pressure
perfusion ﬁxed with 10% neutral buffered formalin, and
imaged by Faxitron cabinet x-ray (Faxitron Bioptics, Tuc-
son, Arizona) to assess the integrity of the implanted devices
followed by gross photographs of the device surface from
the LA while maintaining the relationship of the adjoining
structures. The LAA device and the surrounding LA wall
underwent dehydration in a graded series of ethanol, fol-
lowed by inﬁltration, and were embedded in methyl-
methacrylate plastic. The device was cut along the long axis
of the appendage, stained with toluidine blue and basic
fuchsin, and analyzed under light microscopy. Each slide
was scored for endocardial tissue growth, inﬂammation,
granulation tissue, and ﬁbrin/thrombus deposition using a0 to 4 grading system. For details of methods used to grade
each parameter, see the Online Appendix and Online
Tables 1a and 1b.
Statistical analysis. All results are presented as mean  SD
unless otherwise indicated. Statistical analysis was per-
formed by Sigma Stat (version 3.5, Systat Software, Inc.,
Germany). Measurement results from canine and human
hearts were compared using the unpaired Student’s t test.
A p value of <0.05 was considered signiﬁcant.
Results
LAA and adjacent structures. Demographically, the canine
body and heart weight ranges were 21.5 to 29.5 kg (25.2 
4.5 kg), and 158.9 to 254.4 g (203.4  39.1 g), respectively.
The human hearts included those of 11 men (6 African
Americans and 5 white) and 8 women (3 African Ameri-
cans, 5 white). The height and body weight ranges were
167 to 193 cm (182.4  8.9 cm) and 66 to 143 kg (100.6 
23.8 kg) for men and 155 to 180 cm (170.2  8.1 cm) and
82 to 123 kg (102  14.3 kg) for women. The heart
weights ranged from 350 to 877 g (538  157 g) in men
and 294 to 620 g (430  111 g) in women. Cases were
selected on the basis of absence of congenital heart disease,
and the cause of death was as follows: 5 died from a
noncardiac reason with normal hearts; 4 had conduction
abnormalities and all were young; 4 had hypertensive heart
disease; 2 had dilated cardiomyopathy; 1 had atherosclerotic
heart disease; 1 had myocarditis; 1 had amyloidosis; and 1
died from thrombotic thrombocytopenic purpura. There
was no signiﬁcant difference in the body weight between
men and women; however, height and heart weight was
greater in men although both men and women had higher
heart weight than seen in normal individuals (normal heart
weights for men are 300 to 350 g and for women are 250
to 300 g) (13).
In general, the LAA in both the canine and the human
hearts is an angled, elongated tubular structure overlying the
base of the left ventricle and abutting the pulmonary artery
root, and it is variable in size and shape. From the anterior
view of the heart, the left main coronary and proximal left
anterior descending and LCX arteries are covered by the
appendage. From the LA chamber view, the ostium of the
LAA is typically an oval-shaped oriﬁce. Importantly, the
LAA ostium has close anatomic relationships to LSPV,
annulus of the posterior MV leaﬂet, and left coronary artery
branches, especially the LCX, which courses in the atrio-
ventricular sulcus in close proximity to the ostium of the
LAA. Figures 1 and 2 show the LAA and its adjacent
structures from both the external and internal views of the
heart.
The dimensions of LAA ostium in both the long and
short axes (12.7  1.4 mm  8.2  2.5 mm) in the dogs are
comparable to those of humans (15.3  3.6 mm long
Figure 1. Canine and Human Hearts, External View Illustrating the Relationship of LAA Ostium to Left Coronary Artery
(A, C) Left superior oblique view of left atrial appendage with yellow line indicates measured length of appendage. (B, D) Left atrial appendage (LAA) reﬂected
superiorly to expose left anterior descending (LAD) and left circumﬂex artery (LCX) arteries. Curved red line indicates level of LAA ostium. Note location of the LCX
coronary artery in the atrioventricular sulcus and its proximity to the LAA ostium. AO ¼ aorta; LM ¼ left main artery; LSPV ¼ left superior pulmonary vein; PA ¼
pulmonary artery; RI ¼ ramus intermedius.
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804axis  8.0  1.8 mm short axis) (Table 1). The closest
distances from LAA ostium to both LCX and LSPV were
comparable between canines and humans (p > 0.05).
However, the external length of the appendage in the ca-
nines (31.7  3.0 mm) is signiﬁcantly shorter than that of
humans (39.6  6.8 mm; p ¼ 0.014). The distance from
LAA ostium to MV annulus was also less in canines (7.3 
2.1 mm) than in humans (10.0  1.8 mm; p ¼ 0.004).Figure 2. Opened LAA in the Canine (A) and the Human (B) Hearts, Showing the
Yellow and red double-headed arrows indicate measurements of long and short ax
between LAA ostium and LSPV. Green double-headed arrows indicate the measur
FO ¼ fossa ovalis; other abbreviations as in Figure 1.There were no signiﬁcant differences among the previously
mentioned parameters between men and women. When
measuring the distance from the LSPV directly to the MV
annulus (LSPV-to-MV) using the shortest diameter of the
LAA oriﬁce, the mean distance was 24.2  3.5 mm and
27.5  3.8 mm for the dogs and humans, respectively, and
there was no signiﬁcant difference (p ¼ 0.088) between
them even when the human hearts were enlarged.Oval LAA Ostium and Its Relationship to Adjacent Structures
es of the LAA ostium. Blue double-headed arrows indicate the measurements
ements between LAA ostium and annulus of posterior mitral valve (MV) leaﬂet.
Table 1. Dimensions of the LAA Ostium and the Distances From




(n ¼ 19) p Value
LAA length 31.7  3.0 39.6  6.8 0.014
LAA ostium long-axis diameter 12.7  1.4 15.3  3.6 NS
LAA ostium short-axis diameter 8.2  2.5 8.0  1.8 NS
Distance from LAA ostium to LCX 2.2  0.8 2.4  0.8 NS
Distance from LAA ostium to LAD 12.2  1.6 10.7  2.0 NS
Distance from LAA ostium to LSPV 8.7  1.9 9.5  1.7 NS
Distance from LAA ostium
to MV annulus
7.3  2.1 10.0  1.8 0.004
Values are mean  SD and are given as millimeters.
LAA ¼ left atrial appendage; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex
artery; LSPV ¼ left superior pulmonary vein; MV ¼ mitral valve.
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805Ex vivo study. The WM device (21 mm) conformed
appropriately to the LAA oriﬁce of the canine heart
following deployment. The measured device surface area was
154 mm2. In comparison, the disk of ACP device was
located outside of the LAA oriﬁce, and both the upper and
lower edges of the disk appeared in close proximity to the
LSPV and the MV annulus than the WM device did. For
the 16-mm ACP device, the disk is 20 mm in diameter, and
its surface area is 314 mm2, which resulted in 51% greater
area than that of the WM device.
In vivo study. Eight animals were enrolled in this study. Two
animals were excluded due to complications of the transseptal
procedure. Devices were successfully implanted in the
remaining 6 dogs (n ¼ 3 per device type) without complica-
tions until termination. The maximal oriﬁce diameter of the
LAA device to the LAA ostium ratio and percentage of deviceFigure 3. TEE and Angiogram Was Performed Pre- and Post-Implantation of WM
Monitor Procedure, and Post-Deployment Assessment
Watchman (WM) images are transesophageal echocardiography (TEE) (A) and LAA a
post-implantation angiogram (D). (E to H) The same sequence of images for the Amcompression was similar between the 2 groups. The LAA
ostium by angiography before implantationwas 20.1 1.0mm
for the WM device and 21.0  3.0 mm for the ACP device.
The device oversize was 14.8  0.1% for WM and 15.0 
0.1% for ACP. All devices were appropriately deployed, and
the representative images are shown in Figure 3. A small
(<3 mm) peridevice ﬂow disturbance post-implantation was
detected by TEE in 2 WM animals and 1 of the ACP
implanted animals immediately following device deployment
and diminished at follow-up (Fig. 4). One animal with an
ACP device had a moderate lateral mitral regurgitation
caused by the inferior edge of the disk extending onto theMV
(5 mm beyond the MV annulus by TEE measurement).
Mitral regurgitation was also observed at 28 days and
conﬁrmed during gross examination (Fig. 5). Coronary
angiography showed LCX hinge motion (Online Appendix)
in this animal, however, the other LCX arteries were patent
with TIMI (Thrombolysis In Myocardial Infarction) ﬂow
grade 3.
Histology evaluation. The hearts were within normal limits
grossly in all animals. Faxitron radiography showed that
devices maintained their integrity and expanded symmetri-
cally without visible fractures. No instances of perforation,
laceration, or erosions were observed. Grossly, the device
conformed to the LAA in vivo and was similar to the ex vivo
implantation (Fig. 6), with the disk of the ACP device
extending over the MV annulus, as well as the lateral
ridge between the LAA ostium and the LSPV. The mean
length from the inferior edge of WM to the MV annulus
measured 9.3  1.2 mm. Histologically, WM showed tight
apposition to the surrounding atrial walls and sealed the
appendage lumen. The surface of WM and the centraland ACP To Evaluate LAA Ostium Size, Select Devices,
ngiogram at RAO30 (B), post-releasing WM device (C), and followed by
platzer Cardiac Plug (ACP) device. LAA ¼ left atrial appendage.
Figure 4. Mild Peridevice Flow Was Found Following Both WM and ACP Implantation by TEE
However, the ﬂow was clearly diminished at 28 days. Abbreviations as Figure 3.
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806screw hub were completely covered by neo-endocardial tis-
sue, which was incorporated with focal organized mature
connective tissue with intermittent areas of granulation tis-
sue and organizing ﬁbrin thrombus. In comparison, the
lower edges of the ACP disk extended beyond the MV
annulus and its upper edge impinged the lateral ridge be-
tween the LSPV and the LAA ostium. The disk appeared to
be in loose contact with the LA wall. Only a small portion of
the disk surface was covered by neo-endocardial tissue,
without signiﬁcant coverage of the inferior disk edge and
end-screw hub (Fig. 7). Histopathologically, WM scored a
greater extent of healing with only focal areas of granulation
tissue and less ﬁbrin deposition and inﬂammation as
compared to the ACP device (Table 2).
Discussion
Worldwide, WM and ACP are the 2 most commonly used
devices for transcatheter closure of the LAA for theFigure 5. In 1 Dog, a Moderate Lateral Mitral Regurgitation by TEE Was Found P
The gross specimen conﬁrmed that the inferior edge of disk extended over the mitprevention of thromboembolism from the LAA in patients
with nonvalvular AF. Whereas the separately published
clinical results appear similar for both devices, there have
been no formal clinical or pre-clinical studies comparing
these devices (6–8,14,15). To the best of our knowledge, this
is the ﬁrst translational study to evaluate the inﬂuence of the
anatomical structures located adjacent to the LAA ostium
and the histologic responses following deployment of WM
and ACP in a canine LAA model. In addition to the
observed considerable similarity of the LAA and the relation
to the neighboring structures in both the canine and human
LAA, we also demonstrated that the device conformation to
LAA, as well as the healing of the surface of the device, was
different. The most notable anatomical difference between
the 2 species was shorter distance of the LAA ostium to the
MV annulus in canines versus humans. The observation
from the current study, therefore, conﬁrmed that the canine
model is suitable for pre-clinical evaluation of LAA occlu-
sion devices.ost-ACP Placement, Which Was Persistent Until Follow-Up at 28 Days
ral annulus. Abbreviations as in Figures 2 and 3.
Figure 6. Compared With WM, the Disk of ACP Showed Proximity to the LSPV and MV
Similar observations were noted in the ex vivo (A to D) and in vivo (E, F) samples. Abbreviations as in Figures 1 to 3.
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807LAA is a complex and variable structure in humans,
which is located between the left upper pulmonary vein and
the MV annulus. LAA lies in the atrioventricular groove,
overlying the LCX artery and the great cardiac vein. There
are several adjacent structures such as LSPV, MV, and
LCX around the LAA. The left lateral ridge is a boundary
between the LAA oriﬁces and the LSPV. Su et al. (16)
reported on the anatomy of the LAA and the relationship
to the adjoining structures. The length from LSPV-to-MV
was 30.7  10.7 mm with a range of 15.7 to 57.6 mm. This
range is wider than that measured in the current study. As
no demographic data such as age, sex, height, and weight
was reported by Su et al. (16), it is difﬁcult to compare the
2 studies. Nevertheless, the shortest length from LSPV-to-
MV in the report by Su et al. (16) was 15.7 mm when
crossing short axis of the LAA ostium. This distance is
shorter than the available ACP disk diameters (20 to 36 mm
based on manufacturer’s instructions for use). Because the
disk of ACP is positioned outside of the LAA following
implantation, caution should be exercised when the length of
LSPV-to-MV is short. Before releasing this device, the disk
should appear as concave-shaped to avoid the consequences
of disk edges extending onto the adjacent structures.
Our data also demonstrates implantation of a proper size
of WM resulted in better conformation to the LAAanatomy without affecting the adjacent LAA structures.
Although a mild peridevice ﬂow post-implantation was
detected in 2 animals immediately after WM, the ﬂow was
diminished at follow-up. Consistent with this pre-clinical
study, the PROTECT AF (Percutaneous Closure of the Left
Atrial Appendage Versus Warfarin Therapy for Prevention
of Strokes in Patients With Atrial Fibrillation) clinical sub-
study (17) also reported residual peridevice events, which
occurred in 32% of implanted patients. It should be noted,
however, that this residual peridevice ﬂow (jet5 mm width)
has no clinical consequence, including no association with
any increased risk of thromboembolism in the clinical setting
(17). The incidence of thrombosis was low with or without
ﬂow, 3% and 4% in PROTECT AF, whereas in a recent
small study (n ¼ 34) with ACP implants, TEE at 3 and
6 months identiﬁed thrombosis in 17.6% patients despite
dual antiplatelet therapy (18). Although another single center
study reported 1 case of pericardial effusion and no cases of
thrombosis or stroke out of 100 ACP implants in patients
with a mean age of 73  10 years (8). In comparison to the
WM, the animals that received ACP devices showed that the
disk interfered with the LAA adjacent structures in our pre-
clinical model. First, the upper edge of the disk was found to
encroach on the left lateral ridge between the LSPV and
LAA ostium. Second, our data showed that the lower edge of
Figure 7. Entire Devices’ Histological Sections Through the Mid Area of the LAA
The WM device (A and C) showed the central area of the device covered with a layer of neo-endocardial tissue with tight device apposition to the native LAA wall. The
ACP device (B and D) showed an area of bare ﬂange mesh wires near the inferior edge of the disk; also there was incomplete coverage of the end-screw hub. All
images with toluidine blue and basic fuchsin stain. Abbreviations as in Figures 1 and 3.
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808the disk extended over the MV, which led to peridevice ﬂow
as well as LCX hinge motion in 1 animal. Lastly, the min-
imal distance from LSPV-to-MV was measured in both ca-
nines (24.2  3.5 mm) and humans (27.5  3.8 mm), it was
shorter than disk diameter at least for >24 mm ACP devices
based on its instructions for use (12). These ﬁndings may
have signiﬁcant clinical consequences especially when using
bigger size ACP devices. It is important to pay attention to
the disk interference with the LSPV ﬂow or the MV during
the implantation. More recently, Swaans et al. (19) reported
on the feasibility and safety of performing radiofrequency
catheter ablation in patients with AF followed by WM
implantation. The combination of ablation and LAA closure
in a single procedure may reduce the risk of repeated
transseptal puncture. Because the disk of the ACP is outside
of the LAA ostium with a close proximity to LSPV, the










WM, n ¼ 3* 2.78  1.20 0.56  0.73 1.44  1.24 0.67  1.12
ACP, n ¼ 3* 2.67  0.87 0.22  0.44 1.78  0.97 1.00  0.00
Values are mean  SD. *Each device was cut into 9 sections, and all of the sections were scored.
ACP ¼ Amplatzer Cardiac Plug; WM ¼ Watchman.A previously published pre-clinical canine study demon-
strated complete endothelial cells coverage of the device
with sealing of the device and LA interface at 45 days
following WM placement (9). Consistent with this report,
we observed that the surfaces of all WM devices were
completely incorporated with organizing neo-endocardial
growth consisting of well-organized ﬁbrointimal and gran-
ulation tissue with only minimal ﬁbrin deposition at 28 days.
In comparison, a report of the ACP device (sizes 18 to
22 mm) when implanted in the canine animal model and
examined grossly and histologically at 30 and 90 days had
also shown that it too was covered by “mature neointima”
with focal calciﬁcation and complete occlusion by angiog-
raphy and color ﬂow Doppler (10). However, 1 animal in
the 30-day implant group had a mural thrombus and a
cerebral infarct. The present study conﬁrmed focal uncov-
ered areas at the lower edge of the disk and end-screw hub at
28 days for the ACP cases. Because the mechanism of closure
with the ACP depends on sealing of the disk to prevent
ﬂow into the LAA, poor apposition at the inferior edge
of the LA wall may be an indicator of prolonged healing
response. Delayed device surface healing could potentially
be related to thrombus formation that accompanies any
device implantation (20).
Study limitations. First, although canine LAA anatomy
has many similarities to the human LAA in several pa-
rameters such as the angulation and morphology, it does
not precisely represent the human nonvalvular AF status.
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809In addition, the healthy canine model will have relatively
faster healing properties than human patients would (9).
Therefore, it is uncertain if the anatomy inﬂuences heal-
ing and if the model is predictive of the human diseased
heart. Second, both canine and human hearts were
examined following formalin ﬁxation, resulting in tissue
shrinkage, which may inﬂuence gross morphometric
analysis. Lastly, this pilot study was limited by a small
sample size, and statistical analysis was not performed for
the in vivo study.
Conclusions
When designing medical devices, one should consider not
only the anatomy of the target organ, but also the sur-
rounding structures. Although differences exist, the canine
LAA model closely mimics the human LAA and is the
standard pre-clinical model for evaluation of LAA closure
devices. Differences in conformation of the LAA surround-
ing structures and healing response were noted following
closure of the canine LAA between WM and APC. In this
small pre-clinical study, the WM device does not obstruct or
affect the LAA adjacent structures, resulting in a favorable
surface recovery. In comparison, the oversized ACP could
potentially jeopardize the LAA neighboring structures and
lead to delayed healing. These data are hypothesis generating
and the clinical relevance of these differences should be tested
in larger trials with longer follow-up.
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APPENDIX
For supplemental tables, and accompanying videos, please see the online
version of this paper.
